Evolving Treatment Strategies in the
Management of Metastatic Melanoma: Expert Perspectives in
Immunotherapy
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2018 Fall Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from January 15, 2019 to January 31, 2020 |
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
Bristol-Myers Squibb and Merck & Co.
Description:
Melanoma is the most serious type of skin cancer. It occurs in skins
cells called melanocytes, and while it is predominantly found in the
skin, it can occur in any area of the body that contains melanocytes.
Melanoma will be found in approximately 73,870 people in the United
States in 2018 according to the National Cancer Institute. While it
is the least common amongst skin cancers, it is by far the most
deadly, with 9,940 people expected to die in 2018. Both of those
numbers have been rising in recent years. In the early stages of
melanoma, prognosis is usually good for patients, but when the
melanoma becomes metastatic and spreads to other areas of the body,
prognosis is especially poor.
Upon completion of this
activity, participants will be able to:
-
Assess the latest clinical data
regarding the use of immune checkpoint inhibitors as adjuvant
treatment for patients with advanced melanoma
-
Analyze the role of immunotherapy in
the first-line treatment in metastatic melanoma
-
Explore the role of Anti–PD-1
immunotherapy in metastatic melanoma
-
Identify patients with advanced
melanoma who may benefit from mono- versus combination immune
checkpoint inhibitor-based treatment
-
List immune-related adverse events (irAEs)
that may occur with the use of immune checkpoint inhibitors and
how they should be identified and managed for improved patient
adherence and quality of life
-
Explore managed care considerations
surrounding recent updates in the use of immune checkpoint
inhibitors as adjuvant treatment for patients with advanced
melanoma
Faculty: |
Sanjiv S Agarwala, MD
Professor & Chief
Hematology & Oncology
St Luke’s Cancer Center & Temple University |
Disclosure:
|
Dr.
Agarwala serves on an advisory board for Merck. His
presentation has been peer reviewed for any bias. |
|
Planning Committee:
Bill Williams,
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
to disclose.
Will Williams has no relevant financial relationships to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses (AAMCN) is
accredited as a provider of continuing nursing education by the
American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
nursing credit.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hour toward CMCN recertification
requirements.
This presentation is supported by
educational grants from
Bristol-Myers Squibb and Merck & Co.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |